Exenatide and Brown Adipose Tissue

NCT03002675 on ClinicalTrials.gov · last registry update 2016-12-26

A small phase 4 — 24 participants, against a typical 75. Its estimated completion date, June 2018, has passed with no update to the record. Primary outcome, as filed: The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Ingrid Jazet
Sponsor type: Other
Enrollment: 24
Started: 2016-08
Primary completion: 2018-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.